Transaction Overview - East China Pharmaceutical's subsidiary, East China Pharmaceutical (Hangzhou), has entered into an exclusive commercialization agreement with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. for the oral formulation VC005 in mainland China [1][4] - The agreement includes an upfront payment of 50 million RMB and milestone payments not exceeding 180 million RMB [1][5] Company Profiles - Jiangsu Weikail, established in 2010, focuses on innovative drug development and has a robust pipeline with five clinical projects and several preclinical projects targeting various diseases [2][3] - East China Pharmaceutical (Hangzhou) is a wholly-owned subsidiary of East China Pharmaceutical, primarily engaged in the wholesale and retail of pharmaceutical products and medical devices [1] Product Details - VC005 is a novel, highly selective second-generation oral JAK1 inhibitor, currently in clinical development for several autoimmune diseases, including moderate to severe atopic dermatitis and ankylosing spondylitis [3][4][8] - The product has shown comparable efficacy to existing treatments and is expected to address safety concerns associated with excessive JAK2 inhibition [4][8] Agreement Terms - East China Pharmaceutical (Hangzhou) will act as the exclusive distributor for VC005 in the designated region, while Jiangsu Weikail retains responsibility for the product's research, registration, production, and supply [4][5] - The agreement allows for the potential transfer of marketing authorization rights under certain conditions, with East China Pharmaceutical (Hangzhou) holding priority rights [5] Market Implications - The collaboration aims to meet the unmet clinical needs in the autoimmune disease treatment space, particularly for atopic dermatitis and vitiligo, which have significant patient populations and treatment challenges [6][7][9] - VC005's oral formulation is expected to enhance patient compliance and accessibility, positioning it as a leading treatment option in the autoimmune disease market [8][9] Future Plans - The company plans to continue focusing on clinical needs and patient outcomes while collaborating with domestic and international firms to advance its drug development and commercialization efforts [10]

从AMAC批发零售贸易指数持仓的市场板块来看，深圳证券交易所占比54.80%、上海证券交易所占比 45.20%。 从AMAC批发零售贸易指数持仓样本的行业来看，可选消费占比38.58%、医药卫生占比30.36%、工业 占比23.73%、能源占比2.45%、主要消费占比2.04%、房地产占比1.52%、金融占比0.65%、原材料占比 0.41%、公用事业占比0.26%。 据了解，中基协基金估值行业分类指数依据《中国上市公司协会上市公司行业统计分类指引》中的门类 划分，编制16个门类指数（不包括制造业）；依据制造业门类下的大类划分，编制27个大类指数，共有 43条行业分类指数。该指数以2008年12月31日为基日，以1000.0点为基点。 从指数持仓来看，AMAC批发零售贸易指数十大权重分别为：华东医药（4.85%）、神州数码 （2.99%）、永辉超市（2.86%）、物产中大（2.2%）、上海医药（2.07%）、益丰药房（1.89%）、万 辰集团（1.89%）、九州通（1.76%）、力源信息（1.53%）、香农芯创（1.5%）。 金融界8月11日消息，上证指数上涨0.34%，AMAC批发零售贸易指数 (AMAC批 ...

Core Viewpoint - Huadong Medicine (000963.SZ) has entered into an exclusive commercialization agreement with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. for the oral formulation VC005, which is a second-generation JAK1 inhibitor aimed at treating autoimmune diseases in China [1][2]. Group 1: Agreement Details - Huadong Medicine's subsidiary, Huadong Medicine (Hangzhou) Co., Ltd., will pay an initial payment of 50 million RMB and up to 180 million RMB in milestone payments to Jiangsu Weikail for the exclusive rights to commercialize VC005 in mainland China [1]. - VC005 is designed to selectively inhibit JAK1 while reducing the inhibitory activity on JAK2, potentially addressing safety concerns associated with excessive JAK2 inhibition [1]. Group 2: Clinical Development Status - VC005 has completed Phase II clinical trials for moderate to severe atopic dermatitis, showing comparable efficacy to Upadacitinib, with itch relief observed on the day of administration; it is currently in Phase III trials for this indication [2]. - The clinical trials for active ankylosing spondylitis have completed Phase II, with preparations for Phase III underway [2]. - For rheumatoid arthritis, VC005 has completed Phase Ib clinical trials, and for non-segmental vitiligo, it received IND approval in May 2025 and is set to initiate Phase II clinical trials [2]. - A sustained-release formulation of VC005 is also under simultaneous development [2].

Core Viewpoint - Huadong Medicine (000963.SZ) has entered into an exclusive commercialization agreement with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. for the oral formulation VC005, which is a second-generation JAK1 inhibitor aimed at treating autoimmune diseases [1][2] Group 1: Agreement Details - Huadong Medicine's subsidiary, Huadong Medicine (Hangzhou) Co., Ltd., will pay an upfront fee of 50 million RMB and up to 180 million RMB in milestone payments to Jiangsu Weikail for the commercialization rights of VC005 in mainland China [1] - The agreement officially took effect on August 8, 2025 [1] Group 2: Product Information - VC005 is a novel, potent, and highly selective oral JAK1 inhibitor, currently in clinical development for multiple autoimmune diseases including moderate to severe atopic dermatitis, ankylosing spondylitis, rheumatoid arthritis, and vitiligo [1] - The product has shown comparable efficacy to Upadacitinib in completed Phase II clinical trials for moderate to severe atopic dermatitis, with itch relief observed on the same day of administration [2] - VC005 is currently in Phase III clinical trials for moderate to severe atopic dermatitis and is preparing for Phase III trials for active ankylosing spondylitis [2] - The product has completed Phase Ib trials for rheumatoid arthritis and has received IND approval for non-segmental vitiligo, with Phase II trials set to commence [2] - A sustained-release formulation of VC005 is also under simultaneous development [2]

Core Viewpoint - East China Pharmaceutical Co., Ltd. has entered into a strategic partnership with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. to obtain exclusive commercialization rights for the oral formulation VC005 in mainland China, addressing the urgent medication needs of over ten million patients with autoimmune diseases [2][3]. Group 1: Partnership Details - East China Pharmaceutical's subsidiary, East China Pharmaceutical (Hangzhou) Co., Ltd., will pay an upfront fee of 50 million yuan and up to 180 million yuan in milestone payments for the registration of VC005 [2]. - VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor designed to reduce inflammation and immune cell activation, currently in clinical development for various autoimmune diseases [2]. Group 2: Market Opportunity - The autoimmune disease treatment market presents significant unmet clinical needs due to the diverse types of autoimmune diseases and their complex mechanisms, coupled with a large patient base [2]. - The oral formulation of VC005 offers higher compliance, convenience, and accessibility compared to traditional injectable forms, making it particularly beneficial for patients requiring long-term treatment [3]. Group 3: Strategic Positioning - The autoimmune field is one of the three core therapeutic areas prioritized by East China Pharmaceutical, which has been actively enhancing its capabilities through the introduction of leading global technologies and products [3]. - The addition of VC005 is expected to enrich East China Pharmaceutical's portfolio in the dermatological oral formulation space, creating effective synergies with existing products and strengthening its core competitiveness in the autoimmune sector [3].

Group 1 - The core point of the news is that East China Pharmaceutical has entered into an exclusive commercialization agreement with Jiangsu Weikail for the oral formulation VC005, which is a novel and potent second-generation JAK1 inhibitor aimed at treating autoimmune diseases [1][3] - East China Pharmaceutical will pay an upfront fee of 50 million yuan and up to 180 million yuan in milestone payments for the commercialization rights of VC005 in mainland China [1] - VC005 is currently in phase III clinical trials for moderate to severe atopic dermatitis and has potential applications for other autoimmune diseases such as ankylosing spondylitis, rheumatoid arthritis, and vitiligo [1][2] Group 2 - Jiangsu Weikail, established in 2010, focuses on innovative drug development and has a pipeline that includes five clinical projects and several preclinical projects across various therapeutic areas including cardiovascular, oncology, and autoimmune diseases [2] - East China Pharmaceutical has identified autoimmune diseases as one of its three core therapeutic areas and has been actively enhancing its capabilities in this field, aiming to provide comprehensive treatment solutions for various autoimmune conditions [2][3] - The collaboration with Jiangsu Weikail is expected to enrich East China Pharmaceutical's portfolio in the oral formulation space for dermatological autoimmune diseases and align with its strategy of full coverage in the dermatology pipeline [3]

Core Viewpoint - Huadong Medicine has secured exclusive commercialization rights for the oral formulation VC005 in mainland China through a partnership with Jiangsu Weikail [1] Group 1: Company Overview - Huadong Medicine's subsidiary, Huadong Medicine Hangzhou, will make an initial payment of 50 million RMB and may pay up to 180 million RMB in milestone payments related to registration [1] - VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor aimed at treating inflammatory and autoimmune diseases, currently in Phase III clinical trials for moderate to severe atopic dermatitis [1]

北京商报讯(记者丁宁)8月11日晚间，华东医药（000963）发布公告称，8月8日，公司全资子公司华东 医药(杭州)有限公司(以下简称"华东医药杭州")与江苏威凯尔医药科技股份有限公司(以下简称"江苏威凯 尔")就VC005达成的独家商业化合作协议正式生效。华东医药杭州获得江苏威凯尔的VC005口服剂型于 中国大陆的独家商业化许可权利。 公告显示，华东医药杭州将向江苏威凯尔支付5000万元首付款，以及最高不超过1.8亿元的注册里程碑 付款。 ...

Group 1 - East China Pharmaceutical's subsidiary has secured exclusive commercialization rights for VC005 oral formulation in mainland China, marking a significant addition to its autoimmune pipeline [1] - The strategic partnership involves an initial payment of 50 million RMB and potential milestone payments up to 180 million RMB [1] - VC005 is a novel, potent, and selective second-generation oral JAK1 inhibitor aimed at treating various autoimmune diseases, including moderate to severe atopic dermatitis, ankylosing spondylitis, rheumatoid arthritis, and vitiligo [2][4] Group 2 - The clinical development of VC005 has shown significant efficacy in moderate to severe atopic dermatitis, with a phase III trial currently underway [4] - The drug's mechanism selectively inhibits JAK1 while reducing JAK2 activity, potentially addressing safety concerns associated with excessive JAK2 inhibition [2] - The increasing prevalence of atopic dermatitis in China, with a recurrence rate of 75.9% over seven years, highlights the urgent need for effective treatments in this area [2] Group 3 - Traditional therapies for atopic dermatitis have limitations due to side effects and administration challenges, creating a demand for innovative, long-term management solutions [3] - The global prevalence of vitiligo is approximately 0.5%-2%, and its treatment remains challenging, further emphasizing the need for effective therapies like VC005 [3] - VC005's oral formulation offers higher compliance and convenience compared to traditional injectable therapies, making it a promising option for long-term treatment of autoimmune diseases [4] Group 4 - East China Pharmaceutical is strategically enhancing its autoimmune portfolio, focusing on innovative technologies and products to strengthen its market position [5][6] - The company has a comprehensive pipeline covering various autoimmune conditions, including skin, rheumatology, cardiovascular, and respiratory diseases [6] - The recent approval of its biosimilar product for psoriasis treatment and ongoing clinical trials for other indications demonstrate the company's commitment to expanding its therapeutic offerings [6][7]

格隆汇8月11日丨华东医药(000963.SZ)公布，2025年08月08日，华东医药股份有限公司全资子公司华东 医药(杭州)有限公司(简称"华东医药杭州")与江苏威凯尔医药科技股份有限公司(简称"江苏威凯尔")就 VC005达成的独家商业化合作协议正式生效。华东医药杭州获得江苏威凯尔的VC005口服剂型(简称"许 可产品"或"标的产品")于中国大陆的独家商业化许可权利。华东医药杭州将向江苏威凯尔支付5,000万元 人民币首付款，以及最高不超过1.8亿元人民币的注册里程碑付款。 ...